Recurrent uveitic macular edema managed with intravitreal faricimab injection.

IF 2.9 Q1 OPHTHALMOLOGY Journal of Ophthalmic Inflammation and Infection Pub Date : 2025-03-13 DOI:10.1186/s12348-025-00478-6

Negin Yavari, Dalia El Feky, Frances A Anover, Khiem Nguyen, Azadeh Mobasserian, Quan Dong Nguyen, Christopher Or

{"title":"Recurrent uveitic macular edema managed with intravitreal faricimab injection.","authors":"Negin Yavari, Dalia El Feky, Frances A Anover, Khiem Nguyen, Azadeh Mobasserian, Quan Dong Nguyen, Christopher Or","doi":"10.1186/s12348-025-00478-6","DOIUrl":null,"url":null,"abstract":"Purpose: To present a case of recurrent uveitic macular edema (UME) treated with intravitreal faricimab injection.Methods: Single case report from a tertiary referral center.Observations: A 63-year-old Caucasian female presenting with recurrent UME due to birdshot chorioretinopathy (BSCR) in both eyes. UME had been treated with multiple agents including intravenous methylprednisone, posterior subtenons and intravitreal triamcinolone acetonide injection, dexamethasone implant, mycophenolate mofetil, and adalimumab with limited improvement and development of intolerance. Moreover, optical coherence tomography also revealed recurrence of UME with subretinal fluid in both eyes. After treatment with one dose of intravitreal faricimab injection, complete resolution of UME was achieved and maintained for three months.Conclusion: The findings of this case hint towards the potential simultaneous effect of angiopoietin-2 blockade along with vascular endothelia growth factor A inhibition by faricimab in managing treatment-resistant UME. Nonetheless, more studies focusing on the role of intravitreal faricimab in UME are required.","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"15 1","pages":"25"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906930/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic Inflammation and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12348-025-00478-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To present a case of recurrent uveitic macular edema (UME) treated with intravitreal faricimab injection.

Methods: Single case report from a tertiary referral center.

Observations: A 63-year-old Caucasian female presenting with recurrent UME due to birdshot chorioretinopathy (BSCR) in both eyes. UME had been treated with multiple agents including intravenous methylprednisone, posterior subtenons and intravitreal triamcinolone acetonide injection, dexamethasone implant, mycophenolate mofetil, and adalimumab with limited improvement and development of intolerance. Moreover, optical coherence tomography also revealed recurrence of UME with subretinal fluid in both eyes. After treatment with one dose of intravitreal faricimab injection, complete resolution of UME was achieved and maintained for three months.

Conclusion: The findings of this case hint towards the potential simultaneous effect of angiopoietin-2 blockade along with vascular endothelia growth factor A inhibition by faricimab in managing treatment-resistant UME. Nonetheless, more studies focusing on the role of intravitreal faricimab in UME are required.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

目的：介绍一例复发性葡萄膜炎性黄斑水肿（UME）病例：来自一家三级转诊中心的单例报告：一名 63 岁的白种女性，双眼因鸟枪状脉络膜视网膜病变 (BSCR) 而反复出现 UME。UME 曾接受多种药物治疗，包括静脉注射甲基强的松、后穹隆下和玻璃体内注射曲安奈德、地塞米松植入剂、霉酚酸酯和阿达木单抗，但病情改善有限，并出现了不耐受症状。此外，光学相干断层扫描还发现双眼 UME 复发，并伴有视网膜下积液。经过一剂玻璃体内法尼单抗注射治疗后，UME完全消退并维持了三个月：本病例的研究结果表明，法替单抗在阻断血管生成素-2的同时抑制血管内皮生长因子A，对治疗耐药的UME具有潜在的作用。尽管如此，还需要进行更多的研究，重点探讨法尼单抗在 UME 中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊